Digitunity to Participate in Patterson Foundation Workshop 27-01-2023, 20:07

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

AKWEL: TURNOVER OF €528.8M IN THE FIRST HALF OF 2024 25-07-2024, 22:45